youtube_live
Q3 2026 earnings • in 5 days
See detailschevron_right
CLBT:NASDAQ
Cellebrite DI Ltd
$12.45
arrow_upward
+0.57%(+0.070) 1D
$12.45
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 6, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CLBT...
Open
$12.34
High
$12.51
Low
$12.18
Mkt. cap
3.13B
Avg. vol.
1.86M
Volume
1.61M
P/E ratio
53.67
52-wk high
$19.98
52-wk low
$9.58
EPS
$0.23
Beta
1.06
Shares outstanding
251.34M
No. of employees
1K
Open
$12.34
High
$12.51
Low
$12.18
Mkt. cap
3.13B
Avg. vol.
1.86M
Volume
1.61M
P/E ratio
53.67
52-wk high
$19.98
52-wk low
$9.58
EPS
$0.23
Beta
1.06
Shares outstanding
251.34M
No. of employees
1K
News stories
From web sources and news partners
Zacks
·
1 day ago
BILL Holdings (BILL) Beats Q1 Earnings Estimates
Investing.com
·
2 days ago
Cellebrite appoints Rogerio Rizzi to strategy role
TradingView
·
2 days ago
Cellebrite (CLBT) Appoints Rogerio Rizzi as Strategy EVP
Profile
Cellebrite DI Ltd. is an Israeli digital forensics company headquartered in Petah Tikva that provides tools for law enforcement agencies as well as enterprise companies and service providers to collect, review, analyze and manage digital data. Their flagship product series is the Cellebrite UFED.
Cellebrite's largest shareholder is Sun Corporation, which is based in Nagoya, Japan. Cellebrite has fourteen offices around the world including business centers in Washington, D.C., Munich, and in Singapore. In 2021, the Cellebrite company was valued at approximately $2.4 billion. Wikipedia
About Cellebrite DI Ltd
CEO-
Employees1.28K
Founded1999
Headquarters-
SectorInformation Technology
IndustryApplication software
Websitecellebrite.com
Analyst ratings
Based on 8 analysts giving stock ratings to CLBT in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for CLBT in the last 3 months.
Highest
Current $12.45
$16.00 (+28.51%)
Average
$14.58 (+17.11%)
Lowest
$12.50 (+0.40%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Rudy Kessinger D.A. Davidson | Buy | Maintained | $15.00 | +20.5% | 09/15/2026 |
Jeff Van Rhee Craig-Hallum | Buy | Maintained | - | - | 09/02/2026 |
Frank Takkinen Lake Street | Buy | Reiterated | $15.00 | +20.5% | 08/14/2026 |
Unknown Analyst Deutsche Bank | Buy | Maintained | $14.00 | +12.4% | 08/14/2026 |
Brian Essex J.P. Morgan | Buy | Maintained | $16.00 | +28.5% | 08/14/2026 |
Unknown Analyst J.P. Morgan | Buy | Reiterated | $16.00 | +28.5% | 08/14/2026 |
Mike Cikos Needham | Buy | Maintained | $12.50 | +0.4% | 08/14/2026 |
Shaul Eyal TD Cowen | Buy | Maintained | $15.00 | +20.5% | 08/13/2026 |
Jonathan Ho William Blair | Buy | Maintained | - | - | 08/13/2026 |
Eric Martinuzzi Lake Street | Buy | Reiterated | $21.00 | +68.7% | 05/14/2026 |
Next call in 5 days
Thu, Nov 12, 3:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $0.16
Revenue / Est. (USD)
- / 145.89M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 126.03M | 128.82M | 128.30M | 131.14M |
Cost of goods sold | 20.31M | 19.69M | 22.42M | 25.21M |
Cost of revenue | 20.31M | 19.69M | 22.42M | 25.21M |
Research and development expenses | 28.12M | 29.86M | 35.87M | 35.96M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 58.60M | 58.46M | 60.89M | 63.02M |
Operating expense | 86.72M | 88.32M | 96.76M | 98.98M |
Total operating expenses | 107.04M | 108.02M | 119.18M | 124.19M |
Operating income | 18.99M | 20.80M | 9.12M | 6.95M |
Other non operating income | - | -482.00K | - | -195.00K |
EBT including unusual items | 24.29M | 26.27M | 13.63M | 11.19M |
EBT excluding unusual items | 24.29M | 26.27M | 13.63M | 11.19M |
Income tax expense | 4.10M | 5.01M | 2.70M | 4.82M |
Effective tax rate | 16.88% | 19.07% | 19.77% | 43.05% |
Other operating expenses | - | - | - | - |
Net income | 20.19M | 21.26M | 10.94M | 6.37M |
Net profit margin | 16.02% | 16.50% | 8.53% | 4.86% |
Earnings per share | 0.14 | 0.14 | 0.12 | 0.11 |
Interest and investment income | 5.30M | 5.21M | 4.52M | 5.54M |
Interest expense | - | - | - | - |
Net interest expenses | 5.30M | 5.21M | 4.52M | 5.54M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 21.69M | 24.75M | 16.12M | 15.86M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events